LIfT BioSciences has successfully raised £300K in seed funding to help complete their cutting-edge laboratory work towards developing the world's first cell bank of lab cultured cancer-killing leukocytes later this year. The funding follows on from the initial round of investment worth £150K, which has already accelerated the research and development of the intellectual property assets used to launch the company, building on two decades of fundamental research led by co-founder, Professor Zheng Cui.
The story was covered by BBC News who interviewed LIfT BioSciences' CEO, Alex Blyth, and features home videos of special moments spent with his mother before she sadly passed away with pancreatic cancer.
Footage of the story behind LIfT BioSciences successful fundraising campaign and how it was founded. Reported by BBC News.
The additional funding is already showing great results with LIfT Bio investing in a new assay system with higher throughput and improved accuracy. The research team will now be testing the selective cancer killing ability of their special lab cultured neutrophils in a range of difficult to treat solid tumours, including pancreatic cancer. Currently, there is no curative therapy for inoperable solid tumours. If successful, LIfT could represent The World's First Curative Cell Therapy for Solid Tomours such as Carcinomas and Sarcomas.
LIfT BioSciences begins talks with potential license partners
LIfT BioSciences was selected as one of only thirteen innovative life science companies to represent the United Kingdom for a special trade delegation meeting held in Japan last month. The meeting was coordinated by the Enterprise Europe Network and Innovate UK as part of their Global Business Accelerator Programme which recognises LIfT Biosciences as one of the UK's most promising biotech start-ups. The initiative provides the company with an ongoing platform and network for fostering strategic partnerships.
UK Trade Delegation in Tokyo with Alex Blyth of LIfT BioSciences on the far right, second from the end.
During the trip, Alex Blyth held talks with a number of major Japanese pharmaceutical companies with a view to prospecting licensing partners which will help bring the therapy to patients following the successful initiation and completion of a clinical trial programme.